Discordant effects of a soluble VEGF receptor on wound healing and angiogenesis
- 22 January 2004
- journal article
- Published by Springer Nature in Gene Therapy
- Vol. 11 (3) , 302-309
- https://doi.org/10.1038/sj.gt.3302162
Abstract
Soluble receptors to vascular endothelial growth factor (VEGF) can inhibit its angiogenic effect. Since angiogenesis is involved in wound repair, we hypothesized that adenovirus-mediated gene transfer of a soluble form of VEGF receptor 2 (Flk-1) would attenuate wound healing in mice. C57Bl/6J and genetically diabetic (db/db) mice (each n=20) received intravenous (i.v.) injections of recombinant adenoviruses (109 PFU) encoding the ligand-binding ectodomain of VEGF receptor 2 (Flk-1) or cDNA encoding the murine IgG2 Fc fragment (each n=10). At 4 days after gene transfer, two full-thickness skin wounds (0.8 cm) were created on the dorsum of each animal. Wound closure was measured over 9–14 days after which wounds were resected for histological analysis. Prior to killing, fluorescent microspheres were systemically injected for quantitation of wound vascularity. Single i.v. injections of adenoviruses encoding soluble Flk-1 significantly decreased wound angiogenesis in both wild-type and diabetic mice. Fluorescence microscopy revealed a 2.0-fold (wild type) and 2.9-fold (diabetic) reduction in wound vascularity in Flk-1-treated animals (p<0.05). Impairment of angiogenesis was confirmed by CD31 immunohistochemistry. Interestingly, despite significant reductions in wound vascularity, wound closure was not grossly delayed. Our data indicates that while VEGF function is essential for optimal wound angiogenesis, it is not required for wound closure.Keywords
This publication has 31 references indexed in Scilit:
- The VIVA TrialCirculation, 2003
- Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trialThe Lancet, 2002
- Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transferProceedings of the National Academy of Sciences, 2001
- Gene therapy-mediated expression by tumor cells of the angiogenesis inhibitor flk-1 results in inhibition of neuroblastoma growth in vivoJournal of Pediatric Surgery, 2001
- Vascular-specific growth factors and blood vessel formationNature, 2000
- Angiogenesis in cancer and other diseasesNature, 2000
- Soluble Flt-1 gene therapy for peritoneal metastases using HVJ-cationic liposomesGene Therapy, 2000
- Clinical applications of angiogenic growth factors and their inhibitorsNature Medicine, 1999
- Rescue of Diabetes-Related Impairment of Angiogenesis by Intramuscular Gene Therapy with Adeno-VEGFThe American Journal of Pathology, 1999
- Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutantNature, 1994